The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
the ipf fiasco was addressed immediately . the ' hiccup' was all it was . markuu takes full responsibility . all sorted , in as much as business as usual - until next fundraise . fair play for at least admitting it was a **** up .
moving on..
the rest of the presentation was very encouraging .
ok they will be needing to fundraise after agm - details to follow ( shareholders given some kind of vote on how they would like it to happen ? )
but i think that we will shortly be seeing some very good data on bexmab prior to the agm ( next week he suggests )
also looking towards a bidding process later in year for bex liscencing /partnerships . there are multiple interested parties .
fast track / breakthrough status applied for in aml/mds
new sites
bexmab data is looking so good that markku doesn't expect much resistance from fda in accelerating bex to market .
they only had 7m shares to play with this side of agm - hence the delay in fundraise .
details of agm should be out soon.
what will the sp be like at the fundraise . hard to say . higher ? lower ? rights issue ?
some good news to sway things . we are at very low level given what is coming .
You can log in here -
https://faron.videosync.fi/q4-2023
Usually you can fire in questions as soon as it starts - and they will quite often answer them if they are straightforward enough .
Great feedback as always Sax… Do you know how I can watch the virtual brief at 12.00 today? Thanks in advance
No new info yet on Bexmab today then . Perhaps they want that on a separate day - get the financials done with , and any awkward questions ( I hope they get some ) - then move on with positives .
The excellent BEXMAB data have intensified numerous ongoing partnering discussions, and we are looking forward to advancing these discussions over the coming year.
None of this work would be possible without the ongoing support from our shareholders, to whom I express my sincere thanks. And to my colleagues on the management team, and the wider Faron community, thank you for your continued commitment to making this Company's vision a reality and bringing the promise of bexmarilimab to patients.
Faron have 'Orphan Drug' Status for Bex . This could accelerate the route to market for AML/MDS.
They plan to apply for BLA in early 2025 .
FDA could recommend a rolling P2/3 study - small numbers - low relative cost - then finally - They start getting income !
That changes the game a bit .
Hopefully the market will see this as a great opportunity .
Sax , Faron at this stage IF the Bex IS that good need to be bought out. They will from now on always have the same Issue with raising funds especially after the last episode. AIMO.
Is it to do with some kind of resolution being needed to be passed at AGM ( maybe relating to possible rights issue ) , or is it because they have raised the max amount this year permissible on Aim , or so much so that they can't do it this financial year , and need to use next years allocation ? I could be wrong , but I think that's the most likely reason .
Plus it bought them a bit more time to get the Bexmab update presented - I'm hoping they do it this week - would make sense .
Seems like this is all being dragged out. Convertible loan, then bridging loan then fund raise.
Why not just do a straight up fundraise and get it done with?
Anyone notice that they added in ' and media ' from the previous RNS .
Anything bad and you wouldn't really want the media looking in would you .
Now in the Event Diary on Faron website :
A virtual briefing and Q&A session for investors, analysts and media will be hosted by Dr. Markku Jalkanen, Chief Executive Officer, and James O’B rien, Chief Financial Officer, today, March 13, 2024, at 12:00 PM (GMT) / 2:00 PM (EET).
Show less
Luck , Yes 100%.
Yes Drac, the hype is gone if there was anything bigger than the forum here? For sure there is a professional audience much more pragmatic and knowledgeable than us, just to remind that these forum’s here are not the only truth. No problem but in business matters it takes a while to come out from the “Death Valley”. This is a natural and a dangerous phase after great expectations when still not knowing how it turns out. Financing plays the most critical role in this phase. But at the end it’s the clinical success that matters at first. So what can you say to investors now? We are far from the power point arrays of the expression of various CDs now showing patients healing in various clinical cohorts. We know the market potentials. But I t’s only the approval or any other official indication towards approvals that can bring us further.
For me anyway the shine has gone off Faron.
We will be sitting here until the bridging loan is arranged ( 5m) - then no doubt interested parties will be keen to get involved in the next raise at the best price possible ( will it be the full 35m , or half and half ) . I'm maybe expecting one big raise - but with major input from interested big investors , along with LLS maybe . But we are already at basement level price .
No doubt the Bexmab update will be a cracker - so then its down to how much they can keep the price down for the fundraise vs how many want to get in . Like I said before - if it goes a bit lower , no great shakes unless you need to sell . Try to ignore the SP - and be glad that we are actually going to make progress - towards a much brighter future .
A lot of love has left Faron unfortunately. Very disappointing seeing us at these levels after so many positive updates
Reminds me of listening to Rick Rule , that precious metals windbag , who I like anyway , talking about risk and how he now invests in safer companies etc , but was reminded by his wife that the reason he is where is he is today , is because he hit it big investing in very risky companies . As many millionaires will tell you , you only have to strike lucky once ( I'll tell you that when I get there )
Isn’t there an analyst call at the moment? Does anyone have the link?
*5% (not 0.05)
(This is what happens after writing a post immediately after working on excel)
Do I trust a random person on the internet? No.
Do I use the input of random people on the internet to make investment decisions, no.
So what does it matter if people trust them or not?
Chat related to the stock > chat about people on a stock message board.
FARN is probably worth a punt at this sort of level, maybe 0.05% of your port if you're feeling frisky.
But as someone who's played Pharma for a long time profitably, don't load all your eggs into one basket. That's what casinos are for.
.
U lot trust this Sax fella?
Someone has loaded up today
Great we had this RNS! Now it’s up to the clinical succe and the business development and potential partnering or M&A news.
Recent events are just a hicup... Timo hasn't lost faith in Faron. Anyone who bought more on the dip have done themselves a favor.
Pharma shares are always the long game.
They need 35 million.. now we know officially what every knew unofficially that to prove up bex will cost..
I'm in for the long game and bought more on the drop.
"next BEXMAB phase I read out in mid-March with special focus on durability of bexmarilimab efficacy on HMA-failed MDS patients known to have very short life expectancy post HMA failure"
Looks like the market was just pleased to have an update but for me having to raise £30m at such a low share price is really damaging. Why not raise £10m now and £20m later?